Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT04546906 · clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
20
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.